Boston Scientific Corporation (BSX) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thanks, Mike. Thanks, Larry. Thinking about 20% growth over a sustained number of years of the LRP as conservative just says something about just how impactful Watchman has been as a therapy and I think will continue to be. As we mentioned earlier with Robbie's question, even the currently indicated population is way underpenetrated, and that's why we aren't very comfortable in that 20% growth. over the long-range plan. But I think, you know, to answer your questions about some of the studies that are coming up, let me talk, you know, about them first closure. So that's trial that is going to be reported on AHA. I don't think it's a particularly good read-through for CHAMP. It's a very different European population, a very different primary endpoint, a shorter follow-up. You know, we continue to think that other trials, like PROG-17 and OPTION, honestly give us, you know, really confidence in what we hope that Champion will show. I think in terms of Olon AF and a trial called Ocean that will be reported out at AHA, you know, both of those, first off, if Ocean is confirmatory of Olon AF, that's great news, right, saying that low-risk patients undergoing AF ablation may no longer need stroke prevention. And I want to, you know, remind you all, right, that up until now, except for very select populations, AF ablation was only really indicated as a way of managing patients with significant symptoms from their AF. And so, this supports the continued growth of FARA pulse as patients seek AF ablation in order to come off their blood thinners. But, and this is important, the patients who are currently getting concomitant FARA watch procedures, are not the low-risk patients who were studied in the loan AF. And we have not seen any material impact to concomitant following the ...